Medical Cannabis for Multiple Sclerosis in the UK

Multiple sclerosis (MS) is one of the conditions with the strongest established evidence base for cannabis-based medicines in the UK. Nabiximols (Sativex), a cannabis-derived oromucosal spray, is the only cannabis-based medicine with a UK marketing authorisation, and it is licensed specifically for MS-related spasticity.

What is Multiple Sclerosis?

Multiple sclerosis is a chronic neurological condition in which the immune system attacks the myelin sheath — the protective covering of nerve fibres in the brain and spinal cord. This demyelination disrupts the electrical signals that nerves send and receive, causing a wide range of symptoms that vary between individuals and over the course of the disease.

In the UK, MS is one of the most common neurological conditions affecting young adults. It may follow a relapsing-remitting course, a secondary progressive course, or in fewer cases, a primary progressive course. Symptoms commonly include muscle stiffness and spasms (spasticity), fatigue, neuropathic pain, sleep disturbance, bladder dysfunction, visual disturbances, cognitive difficulties, and mobility impairment. Spasticity in particular is a significant cause of disability and is often inadequately controlled by standard oral antispastic agents such as baclofen or tizanidine.

Medical Cannabis and Multiple Sclerosis — What Does the Evidence Say?

MS represents one of the clearest cases in UK medicine for the clinical use of cannabis-based medicines. Sativex (nabiximols), a standardised extract containing THC and CBD in a 1:1 ratio, has been evaluated in multiple clinical trials for MS spasticity and carries a UK marketing authorisation for this indication. It is recommended by NICE as an option for moderate-to-severe spasticity in adults with MS when other treatments have not provided adequate relief — making it one of the few cannabis-derived medicines with formal NICE guidance in its favour.

Clinical trials have demonstrated that a meaningful proportion of patients with MS spasticity who do not respond adequately to conventional antispastics experience clinically significant reductions in spasm frequency and severity with nabiximols. Patient-reported outcomes regarding pain, sleep, and overall functioning have also been broadly positive in the MS context.

Medical Cannabis for MS Spasticity — What Patients Need to Know

Spasticity is the primary indication for cannabis-based medicines in MS. Moderate-to-severe spasticity that has not responded adequately to conventional antispastic medications — typically baclofen and tizanidine — is the clearest pathway to a prescription.

Nabiximols (Sativex) is the gold standard product for MS spasticity: it is a standardised 1:1 THC:CBD oromucosal spray administered under the tongue or to the inside of the cheek. Response rates in clinical trials have been meaningful, and NICE endorses it as an option when other treatments have failed. Private specialist clinics can prescribe nabiximols where NHS funding is unavailable or declined.

MS-related neuropathic pain is a second major indication. Patients with persistent pain driven by nerve damage — rather than spasticity alone — may also be considered for cannabis-based medicines, often using THC-containing oils or flower alongside or instead of nabiximols.

Getting Sativex on a Private Prescription in the UK

Sativex has NICE guidance supporting its use for MS spasticity, but NHS funding decisions are made locally by Individual Funding Request (IFR) and in practice many patients are refused or face long delays. A private prescription from a licensed specialist clinic is the most direct route for patients who qualify clinically but cannot access NHS funding.

The private prescribing route: book a consultation at a clinic with neurological expertise — Sapphire Medical, Lyphe, or TMCC are among those with documented MS prescribing experience. Bring your neurologist's letters, a list of antispastics tried, and your disease-modifying therapy details. A private nabiximols prescription is dispensed by a specialist pharmacy and typically costs £200 to £400 per month for the medication.

Who Qualifies for a Medical Cannabis Prescription for Multiple Sclerosis?

• Confirmed MS diagnosis: A formal diagnosis of multiple sclerosis, typically made by a neurologist.
• Moderate-to-severe spasticity or neuropathic pain: Symptoms that substantially impair quality of life and daily functioning.
• Failed conventional antispastics: At least two antispastic medications tried — such as baclofen and tizanidine — without adequate symptom control or with intolerable side effects.
• Specialist documentation: Neurologist or MS specialist letters confirming your diagnosis, symptom severity, and treatment history are very helpful and often required.

What to Expect from a Medical Cannabis Consultation for MS

The consultation will focus on your neurological history, the nature and severity of your spasticity or pain, and the treatments you have already tried. The specialist will also review your MS type, disease-modifying therapies, and other current medications.

If nabiximols is prescribed, initial dosing for spasticity is typically titrated over several weeks. Response is formally assessed after a trial period, and treatment continues only in those who demonstrate a meaningful clinical benefit.

How Much Does Medical Cannabis Cost for MS in the UK?

• Initial consultation: £79 to £200 at a private cannabis clinic.
• Monthly medication: £150 to £400 per month depending on product and dose required.
• Follow-up appointments: £50 to £100 per session every one to three months.

Medical Cannabis for MS UK — Clinical Outcomes in 2026

Multiple sclerosis patients are among the most studied populations for cannabis-based medicines in the UK. UK real-world registry data — particularly from the UK Medical Cannabis Registry — provides prescribing-level outcome evidence beyond the original nabiximols clinical trials.

Outcome Domain	Evidence Basis	Clinical Finding
Spasticity (nabiximols)	Multiple RCTs + NICE endorsement	Clinically meaningful spasm reduction in approx. 1 in 3 patients who failed antispastics
Neuropathic pain (MS)	UK registry + RCT data	Significant pain score improvements; most responsive to THC-containing products
Sleep quality	Registry observational data	Sleep disruption frequently co-improves alongside spasticity and pain relief
Bladder symptoms	Small RCT data	Some evidence of reduced urgency and frequency; not a primary licensed indication
Quality of life / mood	Patient-reported outcomes	Overall quality of life improvements frequently reported alongside primary symptom relief

The clearest benefit remains in MS spasticity with nabiximols — this is the only cannabis-derived medicine with a UK marketing authorisation and NICE recommendation, giving it a higher evidential standard than most other cannabis prescribing indications in the UK.

Sativex vs Other Cannabis Products for MS — UK Prescribing in 2026

UK specialists increasingly use a tailored product approach for MS patients rather than nabiximols alone. The appropriate product depends on whether spasticity, pain, or sleep is the primary treatment target.

Product	Format	Primary Use in MS	Monthly Cost (Private)
Nabiximols (Sativex)	Oromucosal spray (1:1 THC:CBD)	MS spasticity — licensed indication, NICE-endorsed	£200–£400
Balanced CBD:THC oil	Oral drops	Neuropathic pain and sleep disruption	£100–£250
THC-dominant flower	Vaporised	Acute spasm relief; rapid onset for breakthrough symptoms	£150–£350
CBD-dominant oil	Oral drops	Anxiety, mood, low side-effect profile for sensitive patients	£80–£180

Nabiximols (Sativex) remains the clinical gold standard for MS spasticity given its specific NICE endorsement. For patients with prominent neuropathic pain alongside spasticity, many UK specialists combine nabiximols with an evening dose of a THC-containing oil or vaporised flower — a combination approach tailored to the patient's individual symptom pattern and daily schedule.

Frequently Asked Questions — Medical Cannabis for MS UK

Is Sativex available on the NHS for MS?

Sativex has NICE guidance supporting its use for MS spasticity, but NHS funding is decided locally and remains inconsistent. Many patients who clearly qualify clinically find their trust does not fund it. A private Sativex prescription from a licensed specialist clinic is the alternative route.

How do I get a private Sativex prescription for MS spasticity?

Book a consultation at a clinic with neurological prescribing experience — Sapphire Medical, Lyphe, and TMCC have documented MS prescribing. Bring your MS diagnosis, neurologist letters, and a history of antispastics tried. A specialist can issue a private Schedule 2 nabiximols prescription if clinically appropriate. Monthly medication cost is typically £200 to £400 for nabiximols.

Can medical cannabis help with MS-related spasticity and pain?

Yes. MS spasticity is the best-evidenced indication for cannabis-based medicines in the UK — nabiximols (Sativex) is specifically licensed for this. MS-related neuropathic pain is also a recognised prescribing indication for private specialists.

Will cannabis-based medicines interact with my MS disease-modifying therapy?

Known significant interactions are limited, but your specialist must be aware of your full medication list — including your DMT — to assess potential interactions thoroughly.

I have progressive MS. Can I still access medical cannabis?

Yes. Patients with secondary or primary progressive MS can be considered if they experience qualifying symptoms such as spasticity or neuropathic pain and have not responded adequately to conventional treatments.

What is the difference between Sativex and other medical cannabis products for MS?

Nabiximols (Sativex) is the only cannabis-based medicine with a UK marketing authorisation specifically for MS spasticity. It is a standardised 1:1 THC:CBD oromucosal spray manufactured to pharmaceutical standards. Other cannabis products — oils, flower — are prescribed off-label for MS-related neuropathic pain or sleep, and have a less formally established evidence base than nabiximols for spasticity specifically.

How long does it take to know if Sativex is working for MS spasticity?

The standard UK trial protocol involves initial titration over two to four weeks followed by a formal response assessment. Clinical guidance recommends continuing nabiximols only in patients who demonstrate a meaningful improvement in spasticity. If there is no clear benefit after a defined trial period, treatment is typically discontinued.